

### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

Claim 1. (original) A multi-dosage liquid pharmaceutical formulation of human growth hormone consisting essentially of human growth hormone at a concentration of from about 5 mg/ml to about 100 mg/ml, phenol, an aqueous buffer, a non-ionic surfactant, said pharmaceutical formulation having a tonicity of from about 100 mosm/kg to about 500 mosm/kg, having a pH of from about 6.1 to about 6.3, and being substantially free of an amino acid excipient.

Claim 2. (original) The pharmaceutical composition according to claim 1, additionally comprising a tonicity-adjusting agent such that the tonicity of the pharmaceutical composition is from about 100 mosm/kg to about 500 mosm/kg.

Claim 3. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the concentration of human growth hormone is from about 6 mg/ml to 14 mg/ml.

Claim 4. (canceled)

Claim 5. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the concentration of phenol is from about 2 mg/ml to about 5 mg/ml.

Claim 6. (canceled)

Claim 7. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the buffer is selected from the group consisting of a phosphate buffer, a citrate buffer, an acetate buffer and a formate buffer.

Claim 8. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the aqueous buffer is a phosphate buffer.

Claim 9. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the buffer has a concentration of from about 5 mM to about 100 mM.

Claim 10. (canceled)

Claim 11. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the buffer is a phosphate buffer having a concentration of about 10 mM.

Claim 12. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the non-ionic surfactant is selected from the group consisting of a poloxamer and a polysorbate.

Claim 13. (canceled)

Claim 14. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the non-ionic surfactant is poloxamer 188.

Claim 15. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, wherein the non-ionic surfactant is present at a concentration of from about 0.05 to about 4 mg/ml.

Claim 16. (canceled)

Claim 17. (canceled)

Claim 18. (original) The pharmaceutical formulation according to claim 2, wherein the tonicity-adjusting agent is selected from the group consisting of sugar, a sugar alcohol, a polyol and a neutral salt.

Claim 19. (currently amended) The pharmaceutical formulation according to ~~claim 17~~ claim 18, wherein the tonicity-adjusting agent is mannitol.

Claim 20. (original) The pharmaceutical formulation according to ~~claim 17~~ claim 2, wherein the tonicity-adjusting agent is present at a concentration of up to 70 mg/ml.

Claim 21. (canceled)

Claim 22. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, said pharmaceutical composition being substantially isotonic.

Claim 23. (currently amended) The pharmaceutical formulation according to claim 1 ~~or claim 2~~, said pharmaceutical composition having a pH of about 6.2.

Claim 24. (original) The pharmaceutical formulation according to claim 2, essentially consisting of

6.67 mg/ml human growth hormone,

2.5 mg/ml phenol,

10 mM sodium phosphate buffer,

30 mg/ml mannitol,

2 mg/ml poloxamer 188,

and having a pH of 6.2.

Claim 25. (currently amended) A kit comprising an injection device and a separate container containing a multi-dosage liquid formulation of human growth hormone according to claim 1 ~~or claim 2~~.